With the Processing License from Health Canada in place, NordicCan is ready to start production of CBD products in Canada. “With the Processing License granted by Health Canada, we are ready to go into full-scale production beginning 2022 at our site, Cogent, located near Vancouver”, says NordicCan CEO Julie Malbaek. “Since we received our

Four new patents open new doors to innovative and precise oral delivery of cannabinoids in the US and Canadian markets. The patents granted to NordicCan, a company in the Fertin Group, cover novel gum base formulations improving oral delivery of cannabinoids. The worldwide interest in cannabinoids for wellness and medical purposes is growing, and with

Fertin Pharma A/S (“Fertin Pharma”), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, today announced the closing of its acquisition by Philip Morris International Inc. (PMI) (NYSE: PM) for an enterprise value of DKK 5.1 billion (approximately USD 820 million[1] ). “We are excited to

Vejle, 1 July, 2021 EQT announced today that it has agreed to sell Fertin Pharma, a specialist contract development and manufacturing organization (CDMO) in innovative oral and intra-oral delivery technologies, to Philip Morris International (PMI) (NYSE: PM). With headquarters in Vejle, Denmark, Fertin Pharma is a leading specialist CDMO in innovative oral and intra-oral delivery

This article was originally published in Danish by the University of Southern Denmark (SDU) and adapted by Fertin Pharma. Read the original article here: Mie er junior specialist i lægemiddelbranchen (mitsdu.dk) Subject knowledge is indispensable, but personality and social skills also play a significant role when a company needs to find the right employee. Mie

IP – a vital framework to create healthier living Every year in April, the global community celebrates World Intellectual Property Day. At Fertin, we recognize the importance of putting Intellectual Property (IP) in the limelight. We believe that IP is a vital framework and powerful tool to advance new ideas and to stimulate cutting-edge research

NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, announced that the Canadian Intellectual Property Office has issued patent numbers CA 3,031,530 and CA 3,035,400 covering the use of cannabinoids within NordicCan’s extruded and compressed chewing gum formulations, including its unique bi-layered compressed gum format. “These patents

It has been more than one year since the COVID-19 pandemic hit the world and changed nearly every aspect of our existence. We are adjusting to a new reality in most parts of our lives, as businesses as well as individuals. Although there is still undoubtedly uncertainty in the days ahead, we would like to

VEJLE, Denmark—March 7, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, has obtained approval a Research License from Health Canada under the Cannabis Act. The Research License is a key element in NordicCan’s strategy of obtaining the processing license for cannabinoid oral dosage formats from the

VEJLE, Denmark—March 5, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, today announced that the United States Patent and Trademark Office (USPTO) has issued it two patents: U.S. Patent No. 10,925,853 and US 10,933,017 cover the use of cannabinoids within NordicCan’s oral dosage formats Zapliq Chewable